{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:16:26Z","timestamp":1768014986348,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-15-RHUS-0004"],"award-info":[{"award-number":["ANR-15-RHUS-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jchf.2020.11.007","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T22:12:34Z","timestamp":1612563154000},"page":"201-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Geographic Region on the COMMANDER-HF Trial"],"prefix":"10.1016","volume":"9","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Byra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"La Police","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep R.","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Eschwege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Toussaint-Hacquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2020.11.007_bib1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ejhf.1585","article-title":"Heart failure around the world","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2020.11.007_bib2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ejhf.326","article-title":"Geographic differences in heart failure trials","volume":"17","author":"Ferreira","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2020.11.007_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart\u00a0Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.11.007_bib4","first-page":"336","article-title":"Income inequality and outcomes in heart failure: a global between-country analysis","volume":"7","author":"Dewan","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2020.11.007_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ahj.2019.08.019","article-title":"Income level and inequality as complement to geographical differences in cardiovascular trials","volume":"218","author":"Ferreira","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2020.11.007_bib6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.11.007_bib7","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2020.11.007_bib8","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.11.007_bib9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ejhf.266","volume":"17","author":"Zannad","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2020.11.007_bib10","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.11.007_bib11","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1093\/eurheartj\/ehz427","article-title":"A\u00a0comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial","volume":"40","author":"Mehra","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2020.11.007_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/jamacardio.2019.1049","article-title":"Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDER HF trial","volume":"4","author":"Greenberg","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2020.11.007_bib13","article-title":"Natriuretic peptide-based inclusion criteria in a heart failure clinical trial: insights from COMMANDER HF","author":"Cunningham","year":"2020","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2020.11.007_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.12052","article-title":"Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology","volume":"159","author":"Baglin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jchf.2020.11.007_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jchf.2020.11.007_bib16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jchf.2020.11.007_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.11.007_bib18","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/eurheartj\/ehw226","article-title":"Geographic variations in the PARADIGM-HF heart failure trial","volume":"37","author":"Kristensen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2020.11.007_bib19","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ejhf.1130","article-title":"Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years","volume":"20","author":"Vaduganathan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2020.11.007_bib20","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT--- new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.11.007_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3122\/jabfm.2017.03.160129","article-title":"Patient beliefs have a greater impact than barriers on medication adherence in a community health center","volume":"30","author":"Gagnon","year":"2017","journal-title":"J\u00a0Am Board Fam Med"},{"key":"10.1016\/j.jchf.2020.11.007_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003551","article-title":"The association between patients' beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey","volume":"3","author":"Sj\u00f6lander","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jchf.2020.11.007_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12939-015-0261-0","article-title":"Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries","volume":"14","author":"Vogler","year":"2015","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.jchf.2020.11.007_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","article-title":"Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories","volume":"52","author":"Blaschke","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jchf.2020.11.007_bib25","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/sim.1296","article-title":"Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems","volume":"21","author":"Pocock","year":"2002","journal-title":"Stat Med"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177920307022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177920307022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:57:23Z","timestamp":1761973043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177920307022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2213177920307022"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2020.11.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Geographic Region on the COMMANDER-HF Trial","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2020.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}